Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds
The present invention pertains to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof, which, , inhibit RAF (e.g., B-RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formula (I): wherein: J is indep...
Saved in:
Main Authors | , , , , , , , , |
---|---|
Format | Patent |
Language | English |
Published |
28.06.2012
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention pertains to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof, which, , inhibit RAF (e.g., B-RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formula (I): wherein: J is independently -O- or -NR-; R, if present, is independently -H or a substituent; R is independently -H or a substituent; Y is independently -CH= or -N=; Q is independently -(CH)-M-(CH)- wherein: j is independently 0, 1 or 2; k is independently 0, 1, or 2; j+k is 0, 1, or 2; M is independently -O-, -S-, -NH-, -NMe-, or -CH-; each of R, R, R, and R is independently -H or a substituent; and additionally R and R taken together may be -CH=CH-CH=CH-; L is independently: a linker group formed by a chain of 2, 3, or 4 linker moieties; each linker moiety is independently -CH-,-NR-, -C(=X)-, or -S(=O)-; exactly one linker moiety is -NR-, or: exactly two linker moieties are -NR-; exactly one linker moiety is -C(=X)-, and no linker moiety is -S(=O)-; or: exactly one linker moiety is -S(=O)-, and no linker moiety is -C(=X)-; no two adjacent linker moieties are -NR-; X is independently =O or =S; each R is independently -H or a substituent; A is independently: Ccarboaryl, Cheteroaryl, Ccarbocyclic, Cheterocyclic; and is independently unsubstituted or substituted; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both and , to inhibit RAF (e.g., B-RAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and conditions that are ameliorated by the inhibition of RAF, RTK, etc., proliferative conditions such as cancer (e.g., colorectal cancer, melanoma), etc. |
---|---|
Bibliography: | Application Number: AU20050297089 |